TORNTPHARM Q4 Results 2026 Preview: Date, Time, Expectations & Key Things To Watch

Torrent Pharmaceuticals enters its Q4 FY26 earnings print following a period of strategic expansion, notably the line-by-line consolidation of J.B. Chemicals & Pharmaceuticals. Investors will be focused on the margin trajectory amidst integration costs and the performance of its newly launched generic semaglutide portfolio.

TORNTPHARM Q4 Results Date and Time

The board meeting is scheduled for 22-May-26 to consider the audited financial results for FY 2025-26 and recommend final dividend for FY 2025-26.

The company has scheduled an investor teleconference on 22nd May 2026 at 06:30 P.M. to discuss Q4 and FY26 results.

What to expect from TORNTPHARM's Q4 FY26 results

In its most recently reported quarter, Torrent Pharmaceuticals posted revenue of Rs. 3,303 Cr, PAT of N/A, and an EBITDA margin of 32.9%. Management has flagged that Q4 performance may be muted due to necessary course corrections and integration of business practices following the acquisition of J.B. Chemicals & Pharmaceuticals. The company continues to monitor the Germany supply disruption, which is impacting 75% of its business there and is expected to take 3 to 4 quarters to resolve via an alternate supplier. Meanwhile, the US business is targeting an annual milestone of $200 million, currently operating at a run-rate of $150-160 million. The upcoming call will likely focus on the integration timeline for J.B. Chemicals and the revenue contribution of the recently launched Sembolic and Semalix products.

Key Things To Watch

Performance vs Guidance Tracking

• Operating EBITDA Margin — Minimum 32.9% for FY26 — On track
• US Revenue — $200 million annually by FY27 — Current run-rate $150-160M
• ANDA Filings — 4-5 filings for FY26 — On track
• Brazil Growth — 10-12% constant currency for FY26 — 10% achieved in Q3
• CAPEX — Rs. 300 crore for FY26 — On track with Rs. 200 crore spent in H1

Strategic Integration and Launches

• JB Pharma consolidation — First line-by-line consolidation of 48.8% stake starting January 21st
• Semaglutide launch — Targeting 10-15% market share for Sembolic and Semalix
• US launch cadence — Targeting 5-7 launches annually

Operational and Regulatory Focus

• Germany supply disruption — Alternate supplier onboarding timeline extended to 3-4 quarters
• Bileshwarpura facility — USFDA inspection concluded April 6-10, 2026 with Zero observations
• India chronic business — Sustained 13% growth in Q3 driving domestic performance